Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

A zinc oxide nanocomposition is modified with a homobifunctional imidoester compound and an antibiotic composition contains the zinc oxide nanocomposition as an active ingredient. Also, a combination preparation contains the zinc oxide nanocomposite and an antifungal agent. The zinc oxide nanocomposite provides an antibiotic composition which is less toxic while exhibiting excellent antibiotic activity, for example, antiviral, antibacterial or antifungal activity. The antibiotic composition is usable to prevent contamination or infection by viruses, bacteria or fungi, inhibit the growth of viruses, bacteria or fungi, or treat infections by viruses, bacteria or fungi.

A zinc oxide nanocomposition is modified with a homobifunctional imidoester compound and an antibiotic composition contains the zinc oxide nanocomposition as an active ingredient. Also, a combination preparation contains the zinc oxide nanocomposite and an antifungal agent. The zinc oxide nanocomposite provides an antibiotic composition which is less toxic while exhibiting excellent antibiotic activity, for example, antiviral, antibacterial or antifungal activity. The antibiotic composition is usable to prevent contamination or infection by viruses, bacteria or fungi, inhibit the growth of viruses, bacteria or fungi, or treat infections by viruses, bacteria or fungi.

A nutritional powder containing oligopeptide includes the following components by weight: oligopeptide powder 55-80%, fruit powder 5-30%, amino acid powder 0.5-5%, multivitamin powder 1.25-5%, mineral powder 0.25-3%, and compound sweetener powder 5-10%.

A nutritional powder containing oligopeptide includes the following components by weight: oligopeptide powder 55-80%, fruit powder 5-30%, amino acid powder 0.5-5%, multivitamin powder 1.25-5%, mineral powder 0.25-3%, and compound sweetener powder 5-10%.

A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A therapeutic hoof treatment composition includes clay, copper sulfate, zinc oxide, triple antibiotic ointment, Tea Tree oil, Clotrimazole cream, and water.

A therapeutic hoof treatment composition includes clay, copper sulfate, zinc oxide, triple antibiotic ointment, Tea Tree oil, Clotrimazole cream, and water.